This is the classic website, which will be retired eventually. Please visit the modernized instead.
Working… Menu

Dual-sided Hypoglossal neRvE stimulAtion for the treatMent of Obstructive Sleep Apnea (DREAM) (DREAM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03868618
Recruitment Status : Active, not recruiting
First Posted : March 11, 2019
Last Update Posted : December 26, 2023
Nyxoah Inc.
Information provided by (Responsible Party):
Nyxoah S.A.

Brief Summary:
A multicenter study to assess the safety and effectiveness of the Genio dual-sided hypoglossal nerve stimulation system for the treatment of obstructive sleep apnea in adults subjects.

Condition or disease Intervention/treatment Phase
Obstructive Sleep Apnea Device: Genio™ system Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 115 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter Study to Assess the Safety and Effectiveness of the Genio Dual-sided Hypoglossal Nerve Stimulation System for the Treatment of Obstructive Sleep Apnea in Adults Subjects
Actual Study Start Date : September 23, 2020
Estimated Primary Completion Date : February 2024
Estimated Study Completion Date : February 2028

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Sleep Apnea

Arm Intervention/treatment
Experimental: Genio Therapy
The Genio™ system is an implantable neurostimulation system comprised of one implanted device
Device: Genio™ system
The Genio™ device is a permanent implant. It is implanted in the chin area and delivers stimulation to both hypoglossal nerve branches (i.e., the left and right branches). The implant does not include a battery or an embedded software and is externally powered.

Primary Outcome Measures :
  1. Incidence of device-related SAEs [ Time Frame: 12 months ]
    Incidence of device-related SAEs recorded during the study for a period of 12 months post-surgery.

  2. Change in Apnea Hypopnea Index (AHI4%) [ Time Frame: 12 months ]
    percentage of responders at 12 months based on AHI4

  3. Change in Oxyhemoglobin Desaturation Index (ODI4%) [ Time Frame: 12 months ]
    percentage of responders at 12 months based on ODI4

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   22 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Body mass index (BMI) limitations
  • Likely suffer from moderate to severe OSA based on history and physical
  • Has either not tolerated, has failed or refused positive airway pressure (PAP) treatments
  • Willing and capable of providing informed consent

Exclusion Criteria:

  • Inadequately treated sleep disorders other than OSA
  • Significant co-morbidities that contraindicates surgery or general anesthesia

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03868618

Show Show 21 study locations
Sponsors and Collaborators
Nyxoah S.A.
Nyxoah Inc.
Layout table for investigator information
Principal Investigator: Tucker Woodson, MD Medical College of Wisconsin
Layout table for additonal information
Responsible Party: Nyxoah S.A. Identifier: NCT03868618    
Other Study ID Numbers: CL-GEN-002033
First Posted: March 11, 2019    Key Record Dates
Last Update Posted: December 26, 2023
Last Verified: April 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Keywords provided by Nyxoah S.A.:
Hypoglossal nerve stimulation
Additional relevant MeSH terms:
Layout table for MeSH terms
Sleep Apnea Syndromes
Sleep Apnea, Obstructive
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
Sleep Disorders, Intrinsic
Sleep Wake Disorders
Nervous System Diseases